Abstract
Prostaglandin F2 alpha (PGF2 alpha) concentrations were measured by radioimmunoassay in homogenised primary tumours from 57 patients with breast cancer. These patients were followed up from 60 to 78 months (median 63 months) after surgery and PGF2 alpha concentrations were related prospectively to metastatic spread and survival. The amounts of PGF2 alpha varied greatly in the different tumours (range 0-90 ng/mg protein), but no significant association was found between PGF2 alpha concentrations and disease free survival, time of relapse, site of recurrence, or overall survival. It therefore seems unlikely that measurement of PGF2 alpha in breast carcinoma is important in the prognosis of the disease.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bennett A., Berstock D. A., Carroll M. A., Stamford I. F., Wilson A. J. Breast cancer, its recurrence, and patient survival in relation to tumor prostaglandins. Adv Prostaglandin Thromboxane Leukot Res. 1983;12:299–302. [PubMed] [Google Scholar]
- Bennett A., McDonald A. M., Simpson J. S., Stamford I. F. Breast cancer, prostaglandins, and bone metastases. Lancet. 1975 May 31;1(7918):1218–1220. doi: 10.1016/s0140-6736(75)92197-2. [DOI] [PubMed] [Google Scholar]
- Bennett A., Stamford I. F., Berstock D. A., Dische F., Singh L., A'Hern R. P. Breast cancer, prostaglandins and patient survival. Br J Cancer. 1989 Feb;59(2):268–275. doi: 10.1038/bjc.1989.56. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
- Droller M. J. Prostaglandins and neoplasia. J Urol. 1981 Jun;125(6):757–760. doi: 10.1016/s0022-5347(17)55196-4. [DOI] [PubMed] [Google Scholar]
- Goodwin J. S. Prostaglandins and host defense in cancer. Med Clin North Am. 1981 Jul;65(4):829–844. doi: 10.1016/s0025-7125(16)31500-0. [DOI] [PubMed] [Google Scholar]
- Granström E., Kindahl H. Radioimmunoassay of prostaglandins and thromboxanes. Adv Prostaglandin Thromboxane Res. 1978;5:119–210. [PubMed] [Google Scholar]
- Honn K. V., Bockman R. S., Marnett L. J. Prostaglandins and cancer: a review of tumor initiation through tumor metastasis. Prostaglandins. 1981 May;21(5):833–864. doi: 10.1016/0090-6980(81)90240-9. [DOI] [PubMed] [Google Scholar]
- Karmali R. A. Review: prostaglandins and cancer. Prostaglandins Med. 1980 Jul;5(1):11–28. doi: 10.1016/0161-4630(80)90086-5. [DOI] [PubMed] [Google Scholar]
- Malachi T., Chaimoff C., Feller N., Halbrecht I. Prostaglandin E2 and cyclic AMP in tumor and plasma of breast cancer patients. J Cancer Res Clin Oncol. 1981;102(1):71–79. doi: 10.1007/BF00410536. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rolland P. H., Martin P. M., Jacquemier J., Rolland A. M., Toga M. Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst. 1980 May;64(5):1061–1070. [PubMed] [Google Scholar]
- Vergote I. B., Laekeman G. M., Keersmaekers G. H., Uyttenbroeck F. L., Vanderheyden J. S., Albertyn G. P., Haensch C. F., De Roy G. J., Herman A. G. Prostaglandin F2 alpha in benign and malignant breast tumours. Br J Cancer. 1985 Jun;51(6):827–836. doi: 10.1038/bjc.1985.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Watson D. M., Kelly R. W., Miller W. R. Prostaglandins and prognosis in human breast cancer. Br J Cancer. 1987 Sep;56(3):367–370. doi: 10.1038/bjc.1987.204. [DOI] [PMC free article] [PubMed] [Google Scholar]